valu usd unless otherwis note
posit top-line
view report anoth solid quarter beat top/bottom
line manag reiter top-lin guid view
conserv slightli rais ep beat
rais ep prior increas pt
new product fuel top-lin growth acceler
cc revenu guidanc vs fce driven
better expect perform rtg mitg fx neg
impact revenu rbce separ non-
gaap ep guidanc vs rbce fce
driven top-lin growth lower tax rate
rtg grew cc guidanc perform
quarter driven neurosurgeri neurovascular
posit contribut titan spine head
manag expect rtg grow y/i organ
mitg outperform compar consensu segment grew
y/i cc top-end guidanc
perform quarter driven surgic innov
quarter manag expect mitg
grow in-lin initi think
cvg grew low-single-digit guidanc similar growth
cvg grew quarter led growth tavr
off-set msd declin de look forward cvg pass
anniversari step lvad anniversari
dcb challeng march cvg also sever new product launches/
indic fuel top-lin growth evolut reveal
linq micra av pacemak tavr low risk indic
manag forecast cvg
diabet grew y/i cc slightli guidanc low-
singl digit segment continu face challeng comp
upgrad program new custom
becom avail due upgrad program requir
defer revenu deliv new product look ahead
manag expect flat slightli
manag expect low-single-digit growth
increas ep increas price target
revenu remain fce increas
y/i cc model assum fx headwind guidanc
moreov increas ep
oper margin expans final pt increas
dissemin produc price prior trade day market close estimate unless otherwis note
forecast least organ growth cvg
rtg mitg expect grow around
diabet group higher rate believ around
guidanc impli ww revenu close
requir addit year estim
therapi innov contribut approxim half
revenu growth balanc come global expans
especi emerg market value-bas health care
tavr micra reveal linq remain key growth
driver cvg five high-growth market within cvg
tavr diagnost mid-teen follow endoven
atrial fibril lvad high singl digit low doubl
digit plan introduc next gener tavr
pend regulatori approv eu risk
indic recent approv us
fuel mid-teen growth tavr enhanc micra
significantli expand potenti market
next-gener icm reveal linq also schedul
launch
double-digit growth emerg market continu
em revenu increas compris
ww revenu approxim em revenu
came greater china middl east africa
latin america switch indirect direct
distribut major impact em growth
margin also made infrastructur invest key
market enabl market access improv penetr
bp increas everi year exclud fx june
investor day compani met target bp
forecast bp ebit margin expans weight
toward enterpris excel program lie
heart achiev target combin target
cc revenu growth ebit margin along debt
reduct lead target compound-annual-growth-rate ep
bloomberg capit market estim upside/downside/target
price target base price-to-earnings ntm multipl
ep y/i key
assumpt underli ep estim mid-single-
digit cc growth basi point cc
oper margin expans fiscal year excess
free cash flow dividend deploy primarili
share buy-back target price-to-earnings price-to-earnings
ntm averag share
upsid scenario base price-to-earnings multipl
ep y/i key assumpt
underli ep estim mid/high-single-
digit revenu growth achiev
combin accret superior perform
neurosurgeri diabet surgic innov
basi point oper margin expans
downsid scenario base price-to-earnings multipl
ep y/i key assumpt underli
ep estim low-single-digit cc revenu growth
flat oper margin year-over-year
materi contribut share repurchas
price target base ep estim y/i target
price-to-earnings price-to-earnings ntm averag share key assumpt
underli ep estim mid-single-digit organ top-line growth
driven new launch continu strength core franchis basi point
oper margin expans compani realiz benefit
enterpris excel program place excess free cash flow
dividend deploy primarili share buy-back price target basi
risk rate price target
lacklust growth key franchis includ pace defibril system atrial
fibril tavr drug-elut stent surgic innov brain pain therapi spine
inabl achiev target cost save manag believ achiev billion
gross save end enterpris excel program
project save fail materi ep estim could risk
risk price target rate includ potenti regulatori delay reject
failur devic clinic trial weaken demand key market price pressur weak
util trend fx
lead world-wide medic technolog compani engag manufactur
sell device-bas medic therapi compani oper four segment cardiac
vascular group restor therapi group diabet group minim invas
million except ep fy april
interest expens net
